Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANT-050
- Development stage
- Preclinical
- Lead developer
- Antikor Biopharma
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ANT-050 is a preclinical-stage VH-VH based bivalent fragment-drug conjugate (FDC) being developed by Antikor Biopharma, in partnership with Essex Biotechnology, for the treatment of solid tumors, including gastric and pancreatic cancers. Utilizing Antikor's proprietary FDC platform, ANT-050 is designed to combine the high specificity of miniaturized antibody fragments (single-chain variable fragments or scFvs) with potent cytotoxic payloads. This small-format conjugate is engineered to achieve rapid and deep tumor penetration, faster systemic clearance, and a wider therapeutic index compared to conventional antibody-drug conjugates (ADCs).
- Other names
- VH-VH based bivalent fragment drug conjugate
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on ANT-050.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANT-050.